These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 28817603)

  • 1. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling.
    Park IA; Hwang SH; Song IH; Heo SH; Kim YA; Bang WS; Park HS; Lee M; Gong G; Lee HJ
    PLoS One; 2017; 12(8):e0182786. PubMed ID: 28817603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
    Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
    Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
    Wang K; Shen T; Siegal GP; Wei S
    Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer.
    Lee H; Lee HJ; Song IH; Bang WS; Heo SH; Gong G; Park IA
    In Vivo; 2018; 32(6):1561-1569. PubMed ID: 30348717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer.
    Lee HJ; Park IA; Song IH; Shin SJ; Kim JY; Yu JH; Gong G
    J Clin Pathol; 2016 May; 69(5):422-30. PubMed ID: 26475777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
    Kim JY; Heo SH; Choi SK; Song IH; Park IA; Kim YA; Park HS; Park SY; Bang WS; Gong G; Lee HJ
    Virchows Arch; 2017 Apr; 470(4):381-389. PubMed ID: 28185053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.
    Lee HJ; Song IH; Park IA; Heo SH; Kim YA; Ahn JH; Gong G
    Oncotarget; 2016 May; 7(21):30119-32. PubMed ID: 27121061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase II╬▒ in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.
    Forero A; Li Y; Chen D; Grizzle WE; Updike KL; Merz ND; Downs-Kelly E; Burwell TC; Vaklavas C; Buchsbaum DJ; Myers RM; LoBuglio AF; Varley KE
    Cancer Immunol Res; 2016 May; 4(5):390-9. PubMed ID: 26980599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
    Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
    Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
    Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
    Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating lymphocytes and CD8
    Vihervuori H; Autere TA; Repo H; Kurki S; Kallio L; Lintunen MM; Talvinen K; Kronqvist P
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3105-3114. PubMed ID: 31562550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
    Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
    Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-bet
    Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
    Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
    Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
    Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
    Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
    Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
    Sasaki R; Horimoto Y; Yanai Y; Kurisaki-Arakawa A; Arakawa A; Nakai K; Saito M; Saito T
    Anticancer Res; 2021 Apr; 41(4):2133-2140. PubMed ID: 33813424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
    Baram T; Erlichman N; Dadiani M; Balint-Lahat N; Pavlovski A; Meshel T; Morzaev-Sulzbach D; Gal-Yam EN; Barshack I; Ben-Baruch A
    Cells; 2021 Jun; 10(6):. PubMed ID: 34201054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.